News

YGION Biomedical GmbH, a company specializing in personalized neoantigen-based cancer vaccines, has successfully completed a Series A financing round, securing €15 million from an Austrian private trust

Read more...

Imvax, Inc., a biotechnology company specializing in personalized immunotherapies derived from whole tumors, has successfully enrolled participants in its Phase 2b clinical trial for IGV-001, designed for patients

Read more...

Atara Biotherapeutics, Inc., a leading player in T-cell immunotherapy, has achieved a significant milestone by submitting a Biologics License Application to the U.S. Food and Drug Administration

Read more...

Rila Therapeutics, a biotech company dedicated to combating chronic fibrotic diseases, has announced the dosing of the first group of subjects in a phase 1 trial of RLA-23174 in China, in collaboration with Yingli Pharmaceutical

Read more...

Arrowhead Pharmaceuticals, Inc. has announced new interim clinical findings on ARO-RAGE, an RNAi-based therapy designed to treat inflammatory lung conditions such as asthma, during the American Thoracic Society

Read more...

Drug Farm announced today that the U.S. Food and Drug Administration has given the green light to the Investigational New Drug application for DF-003. This oral alpha-kinase 1

Read more...

Flamingo Therapeutics has initiated a new Investigator-initiated Trial aimed at assessing the safety and effectiveness of danvatirsen in patients with acute myeloid leukemia and myelodysplastic syndrome

Read more...

Verrica Pharmaceuticals Inc., specializing in dermatology therapeutics, has announced a significant update to its licensing agreement with Torii Pharmaceutical Co. Ltd. This involves collaborating on a global pivotal Phase 3 clinical trial of YCANTH®

Read more...

Petros Pharmaceuticals, Inc., a company focused on improving access to medication through over-the-counter drug development programs, has announced that all strengths of its prescription erectile dysfunction medication,

Read more...

AriBio Co., Ltd., a biotechnology company dedicated to leading the treatment of neurodegenerative diseases, announced that the National Medical Products Administration of China, along with the Center for Drug Evaluation

Read more...

Brii Biosciences Limited, a leading biotechnology company, announced today that the National Medical Products Administration's Center for Drug Evaluation has granted Breakthrough Therapy Designations

Read more...

PharmaTher Holdings Ltd., a specialty pharmaceutical company, has received an Amendment Acknowledgment Letter from the U.S. Food and Drug Administration for its Priority Original Abbreviated New Drug Application

Read more...

The Jackson Laboratory, a nonprofit biomedical research organization, has forged a strategic partnership with AbTherx, a biotechnology innovator, to advance antibody discovery and expedite the development of vital new therapies.

Read more...

Metaphore Biotechnologies, in conjunction with Flagship Pioneering, has announced a significant research collaboration with Novo Nordisk aimed at developing innovative therapeutics for managing obesity.

Read more...

Neurocrine Biosciences, Inc., has announced the initiation of its Phase 1 clinical trial to evaluate NBI-1076986, a novel compound targeting the M4 subtype-selective muscarinic acetylcholine receptor.

Read more...

CEL-SCI Corporation has recently shared positive news from its discussion with the U.S. Food and Drug Administration regarding the approval pathway for its cancer immunotherapy, Multikine

Read more...

Acepodia, a biotech firm in the clinical stages, has released initial findings from its Phase 1 dose escalation trial of ACE1831. This therapy, a fusion of an anti-CD20 antibody with allogeneic gamma delta T cells, is aimed at treating non-Hodgkin's lymphoma

Read more...

Invivyd, Inc., a biopharmaceutical company specializing in combating severe viral infections, has disclosed its intention to seek emergency use authorization from the U.S. Food and Drug Administration for pemivibart.

Read more...

TC BioPharm, a biotechnology company in the clinical stage, has recently announced its intention to acquire a privately-held biotechnology company. This company specializes in the development of Chimeric Antigen Receptor T-cell

Read more...

AsclepiX Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in computational biology from Johns Hopkins to develop peptides for treating retinal diseases, has announced the completion

Read more...

Gossamer Bio, Inc., a biopharmaceutical company focusing on the clinical development and commercialization of seralutinib for treating pulmonary arterial hypertension and pulmonary hypertension

Read more...

Amolyt Pharma has received Fast Track designation from the FDA for its Phase 3 development targeting hypoparathyroidism. The Fast Track process expedites drug review for serious conditions with unmet medical needs.

Read more...

Remix Therapeutics, a biotechnology company in the clinical stage, is pioneering the development of small molecule therapies targeting RNA processing to combat the root causes of diseases. Today, they announced a significant step forward with

Read more...

Tenax Therapeutics, Inc. has announced that the United States Patent and Trademark Office has granted the company a patent covering the use of several forms of levosimendan,

Read more...

Wave Life Sciences Ltd. has announced the approval of its first clinical trial application for the RestorAATion-2 trial of WVE-006, a novel RNA editing oligonucleotide designed to treat alpha-1 antitrypsin deficiency

Read more...

X4 Pharmaceuticals announced today that the U.S. Food and Drug Administration has approved XOLREMDI™ capsules for patients aged 12 and above diagnosed with WHIM syndrome

Read more...

Amgen recently announced its plans to submit a Marketing Authorization Application to the European Medicines Agency for teprotumumab, a fully human monoclonal antibody designed to treat moderate to severe Thyroid Eye Disease

Read more...

Freedom Biosciences, Inc. has received notification from the U.S. Food and Drug Administration (FDA) greenlighting the initiation of its FREE001-TRD-201 study, a Phase 2a clinical trial for FREE001

Read more...

Deverra Therapeutics, Inc., a biotechnology company specializing in developing advanced cell therapies for cancer and other serious diseases, has announced that the U.S. Food and Drug Administration

Read more...

Ascendis Pharma A/S has announced that the Medicines & Healthcare Products Regulatory Agency in the United Kingdom has given the green light to YORVIPATH®. This marks a significant step forward as it's now authorized for treating adults

Read more...

Tiziana Life Sciences, Ltd., a biotech company focused on developing innovative immunomodulation therapies through unique drug delivery methods, has received approval from the U.S. Food and Drug Administration

Read more...

Acadia Pharmaceuticals Inc. has announced that Health Canada has accepted its New Drug Submission for trofinetide, a potential treatment for Rett syndrome, a rare neurodevelopmental disorder.

Read more...

Immunovia has unveiled a significant advancement with its next-generation pancreatic cancer test, aimed at enhancing survival rates through early detection. The new test has successfully met primary and secondary endpoints

Read more...

Ocugen, Inc., a biotechnology company specializing in gene and cell therapies as well as vaccines, has reported the completion of dosing in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410

Read more...

GenFleet Therapeutics, a leading biotechnology company specializing in advanced therapies for oncology and immunology, has received approval from the US Food and Drug Administration

Read more...

Saghmos Therapeutics, Inc, a privately owned biopharmaceutical company, has revealed its collaboration with the Duke Clinical Research Institute (DCRI) to optimize and strategize the operationalization of its Phase 3 study

Read more...

AmplifyBio, a Contract Development and Manufacturing Organization and Contract Research Organization, and RNAV8 Bio, a rising startup specializing in mRNA engineering platforms,

Read more...

Arrivo Bio has announced a significant advancement in the fight against major depressive disorder by initiating dosing for the first patient in the SP-624-202 clinical trial.

Read more...

Walden Biosciences, Inc., a privately funded clinical development company specializing in innovative therapies for kidney diseases, has announced the results from its Phase 1+ clinical trial of WAL0921 in healthy individuals. WAL0921 represents Walden's novel

Read more...

ORIC Pharmaceuticals, Inc. has completed the dose escalation phase of the Phase 1b trial for ORIC-114, a treatment targeting advanced solid tumors with EGFR and HER2 exon 20 alterations or HER2 amplifications

Read more...

Oncocyte Corporation, a company specializing in precision diagnostics, has announced a partnership with Bio-Rad Laboratories, a prominent player in life science research and clinical diagnostics.

Read more...

Ocugen, Inc., a biotechnology company specializing in gene and cell therapies, and vaccines, has announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency

Read more...

Lonza and NeuroSense Therapeutics Ltd. have formed a collaboration to investigate biological changes occurring in individuals with neurodegenerative diseases, including ALS. NeuroSense will have access to Lonza's advanced expertise and capabilities

Read more...

Corvus Pharmaceuticals, Inc. has initiated a Phase 1 clinical trial to evaluate soquelitinib in patients with moderate to severe atopic dermatitis. This trial, which is randomized, double-blind, and placebo-controlled,

Read more...

Ocugen, Inc., a biotechnology firm specializing in the discovery, development, and commercialization of innovative gene and cell therapies, along with vaccines, has announced the approval of its Investigational New Drug

Read more...

Dizal announced today that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to its drug sunvozertinib as the primary treatment for patients

Read more...

IASO Biotechnology, a prominent biopharmaceutical company specializing in innovative cell therapy and antibody products, is excited to announce the approval of the Investigational New Drug application by the U.S. Food and Drug Administration

Read more...

Basilea Pharmaceutica Ltd, based in Allschwil and traded on the SIX Swiss Exchange under the symbol BSLN, has announced that the US Food and Drug Administration has given approval for ZEVTERA®

Read more...

Genmab A/S and ProfoundBio, Inc. have announced a definitive agreement today for Genmab's acquisition of ProfoundBio in an all-cash deal. ProfoundBio, a privately-owned clinical-stage biotechnology company, specializes in developing next-generation ADCs

Read more...

Today, Scantox, along with its majority owner Impilo, has successfully concluded the acquisition of QPS Neuropharmacology, a leading contract research organization specializing in drug discovery for neurodegenerative diseases,

Read more...

RemeGen Co. Ltd., a prominent biotechnology company, has recently secured Fast Track Designation from the United States Food and Drug Administration for its innovative drug Telitacicept

Read more...

Xcell Biosciences Inc. recently expanded its collaboration with Labcorp, a prominent laboratory services provider, by incorporating new elements into their research agreement. In this enhanced partnership

Read more...

Merz Therapeutics, a subsidiary of the Frankfurt-based Merz, has entered into an agreement to acquire two marketed drugs from the NASDAQ-listed US company Acorda Therapeutics. This deal is expected to significantly contribute to Merz Therapeutics' accelerated growth strategy.

Read more...

Applied Therapeutics, Inc. has announced an extension in the review period by the U.S. Food and Drug Administration for their New Drug Application for govorestat, intended for treating Classic Galactosemia

Read more...

Milestone® Pharmaceuticals Inc, a biopharmaceutical company focusing on innovative cardiovascular medicines, has announced the resubmission of its New Drug Application

Read more...

Renexxion Ireland Limited, in partnership with Dr. Falk Pharma GmbH in Europe, has obtained clearance from the U.S. Food and Drug Administration for its Investigational New Drug application concerning

Read more...

IntraBio Inc announced today that the U.S. Food and Drug Administration has accepted its New Drug Application for IB1001, intended for treating Niemann-Pick disease Type C. The application

Read more...

Amneal Pharmaceuticals, Inc. has announced that it received approval for its Abbreviated New Drug Application from the U.S. Food and Drug Administration for ciprofloxacin and dexamethasone

Read more...

ULTOMIRIS® has recently obtained approval in the United States as the first and only long-acting C5 complement inhibitor for the treatment of adult patients diagnosed with anti-aquaporin-4

Read more...

Molecure S.A. is a biotechnology company specializing in the development of innovative drugs for treating various incurable diseases. The company focuses on leveraging its expertise

Read more...

Today, the U.S. Food and Drug Administration has approved Duvyzat, an oral medication, for treating Duchenne Muscular Dystrophy in patients aged six and above. Duvyzat is notable for being the first nonsteroidal drug

Read more...

Cabaletta Bio, Inc. has recently gained Orphan Drug Designation from the U.S. Food and Drug Administration for its investigational therapy, CABA-201, aimed at treating systemic sclerosis

Read more...

Puma Biotechnology, Inc., a biopharmaceutical company, has received approval from the U.S. Food and Drug Administration for its Investigational New Drug Application concerning alisertib. This allows Puma to progress with clinical trials

Read more...

Takeda has recently announced that the U.S. Food and Drug Administration approved the supplemental New Drug Application for ICLUSIG®. This approval expands the usage of ICLUSIG to treat adult patients

Read more...

Telix Pharmaceuticals Limited has revealed a new partnership for its QDOSE® dosimetry software platform with ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH

Read more...

KeChow Pharma, a prominent pharmaceutical company specializing in developing and commercializing innovative small molecule therapeutics for cancer, has reached a significant achievement.

Read more...

Optinose , a pharmaceutical company that focuses on treatments for ear, nose, and throat issues as well as allergies, has announced that the U.S. Food and Drug Administration has granted approval for XHANCE®

Read more...

Sino Biological, Inc., a major biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, has forged a notable partnership with Rapid Novor, Inc, headquartered in Toronto

Read more...

ProteoNic Biosciences, a leader in vector technology and services for biologics production, has announced a partnership with Ginkgo Bioworks, known for its advancements in cell programming and biosecurity

Read more...

Arctic Therapeutics ehf, an Icelandic drug development company, in collaboration with Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in treatments for retinitis pigmentosa

Read more...

Boehringer Ingelheim and Sosei Group Corporation have recently announced a global collaboration and an exclusive option-to-license agreement. The primary goal of this partnership

Read more...

Eilean Therapeutics LLC, a biopharmaceutical company focusing on discovering and developing small molecule inhibitors for hematologic and solid malignancies, has announced a significant milestone.

Read more...

Regeneron Pharmaceuticals, Inc. recently made a significant announcement regarding pediatric healthcare. The U.S. Food & Drug Administration has extended the approval of Praluent®

Read more...

Apex Labs Ltd., a pharmaceutical company at the forefront of mental health treatment using psilocybin, is excited to announce the submission of a provisional patent application to the United States Patent and Trademark Office

Read more...

Mind Medicine Inc., a company specializing in the development of treatments for brain health disorders, has received a breakthrough designation from the FDA for its MM120 program aimed at treating generalized anxiety disorder

Read more...

Ludwig Enterprises, Inc, a US-based biotechnology company, is excited to announce the successful filing of its provisional patent titled "mRNAs Differentially Expressed in Colorectal Cancer,

Read more...

Mainz Biomed N.V, a leader in molecular genetics diagnostic solutions for early cancer detection, has announced a strategic collaboration with Trusted Health Advisors, a prominent player in supporting the launch and management

Read more...

YolTech Therapeutics, a leading biotechnology company specializing in in vivo gene editing therapies for rare genetic diseases, has achieved a significant milestone with the approval of the YOLT-201 investigational new drug application by the Center for Drug Evaluation

Read more...

Vivoryon Therapeutics N.V. recently disclosed the top-line findings from its Phase 2b European VIVIAD trial of varoglutamstat , an oral glutaminyl cyclase inhibitor being explored for early Alzheimer’s disease

Read more...

Coave Therapeutics, a genetic medicine company focused on developing innovative therapies, is pleased to announce its receipt of a grant from the ALS Association, part of a $2.9 million allocation to six organizations. These grants support the advancement

Read more...

NeuroBo Pharmaceuticals, Inc. has obtained its first site Institutional Review Board approval from Dr. Alexander Prezioso, Investigator at Clinical Pharmacology of Miami in Hialeah, FL, to initiate the Phase 1 clinical trial

Read more...

Form Bio and Ginkgo Bioworks have unveiled an innovative collaboration to revolutionize AAV gene therapy design and development. This partnership combines Ginkgo's expertise in cell programming and biosecurity

Read more...

Incyte has disclosed that the U.S. Food and Drug Administration has accepted the Biologics License Application for axatilimab, an anti-CSF-1R antibody, for Priority Review. This application targets the treatment of chronic graft-versus-host disease

Read more...

BeiGene, Ltd. declared today that the U.S. Food and Drug Administration has accepted its Biologics License Application for TEVIMBRA® combined with fluoropyrimidine- and platinum-containing

Read more...

Genmab A/S and AbbVie have jointly announced that the U.S. Food and Drug Administration has given Priority Review status to their supplemental Biologics License Application

Read more...

XYRA LLC, a private biopharmaceutical company focused on developing innovative therapies for cardiac rhythm disorders, is pleased to announce an agreement with the FDA regarding the next steps for its drug

Read more...

Curi Bio, a leader in developing human stem cell-based platforms for drug discovery, has announced a Memorandum of Understanding for scientific collaboration with Genetox and DreamCIS

Read more...

Alpha Cognition Inc, also known as Alpha Cognition, a biopharmaceutical company focused on developing novel treatments for severe neurodegenerative disorders, is excited to announce the submission of a new

Read more...

MRM Health, a biopharmaceutical company in the clinical stage, has received approval from regulatory and ethics committees to commence an observational cross-sectional clinical trial. This trial aims to identify specific microbial and metabolic patterns

Read more...

Disc Medicine, Inc, a biopharmaceutical company focusing on innovative treatments for severe hematologic diseases, has announced that the United States Food and Drug Administration

Read more...

AffaMed Therapeutics, a prominent biotechnology company specializing in developing and commercializing innovative pharmaceutical and surgical products for unmet needs in ophthalmology

Read more...

Certa Therapeutics, a biotechnology company specializing in precision therapies for inflammatory and fibrotic diseases, has announced that the U.S. Food and Drug Administration has granted Fast Track Designation for its investigational therapy

Read more...

Iovance Biotherapeutics, Inc, a biotechnology company focused on developing novel polyclonal tumor infiltrating lymphocyte cell therapies for cancer patients, has received approval from the U.S. Food and Drug Administration

Read more...

Intellia Therapeutics, Inc. and ReCode Therapeutics have announced a collaborative effort to develop innovative genomic medicines for cystic fibrosis, a genetic disease that affects various organs,

Read more...

Bristol Myers Squibb has shared that the U.S. Food and Drug Administration accepted the supplemental New Drug Application for Augtyro™ aimed at treating solid tumors in adults and pediatric patients aged 12 and above

Read more...

Atara Biotherapeutics, Inc, a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases,

Read more...

DelSiTech Ltd., a company specializing in clinical-stage drug delivery and development, has announced a global license and development agreement with Tolmar International Ltd., a fully-integrated pharmaceutical company.

Read more...

Krystal Biotech, Inc, a biotechnology company, announced today that the U.S. Food and Drug Administration has granted Fast Track Designation for inhaled KB707. This designation aims to expedite the development

Read more...

HTuO Biosciences, a biotech company specializing in molecular simulation for drug discovery, has recently joined Johnson & Johnson Innovation - JLABS as a resident virtual company.

Read more...

Corvus Pharmaceuticals, Inc, a biopharmaceutical company focusing on clinical-stage developments, announced new findings on soquelitinib, its leading ITK inhibitor program

Read more...

Disc Medicine, Inc, a company focused on developing treatments for serious hematologic diseases, announced that the United States Food and Drug Administration has granted Orphan Drug Designation to DISC-3405 for treating polycythemia vera patients.

Read more...

Nascent Biotech, Inc. recently announced a research collaboration agreement with Manhattan BioSolutions, Inc. The collaboration aims to investigate antibody-drug conjugates utilizing Nascent’s lead clinical candidate

Read more...

Calibr-Skaggs Institute for Innovative Medicines, the nonprofit arm of Scripps Research focusing on drug development, has revealed an expansion in its collaboration with AbbVie. This extension aims to further investigate Calibr-Skaggs' switchable CAR-T

Read more...

Triumvira Immunologics, a clinical-stage biotech company focusing on developing innovative autologous and allogeneic T cell therapies for solid tumors, has announced the initiation of dosing for the first patient in its TACTIC-3 trial

Read more...

Vanda Pharmaceuticals Inc. announced today, it received notification from the U.S. Food and Drug Administration regarding its supplemental New Drug Application for HETLIOZ® aimed at treating insomnia characterized by difficulties with sleep initiation. The FDA

Read more...

Regeneron Pharmaceuticals, Inc. recently announced that the European Medicines Agency has accepted the Marketing Authorization Application for linvoseltamab, a bispecific antibody

Read more...

Independent Pharmacy Cooperative, the leading group purchasing organization owned by independent pharmacies nationwide, proudly announces an exclusive distribution partnership with TheracosBio

Read more...

Cabaletta Bio, Inc. has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for CABA-201, an investigational therapy developed to treat idiopathic inflammatory myopathies

Read more...

Ascendis Pharma A/S has declared the launch of YORVIPATH® in Germany and Austria. YORVIPATH is a parathyroid hormone replacement therapy designed for adults dealing with chronic hypoparathyroidism.

Read more...

Lexaria Bioscience Corp. has officially submitted its Investigational New Drug application for the anticipated U.S. phase 1b hypertension clinical trial, HYPER-H23-1, featuring DehydraTECH-CBD

Read more...

Synthekine Inc., a company specializing in engineered cytokine therapeutics, has recently announced a global collaboration with Sanofi to jointly develop and commercialize

Read more...

Rise Therapeutics, a biotechnology company in the clinical stage, has successfully enrolled its initial participant in the Phase 1 clinical trial for R-2487, a prospective treatment for rheumatoid arthritis

Read more...

Sionna Therapeutics, a life sciences company focused on advancing treatments for cystic fibrosis , has initiated a Phase 1 clinical trial for SION-109 after receiving approval for its Investigational New Drug

Read more...

Cognito Therapeutics, a neurotechnology company specializing in the development of disease-modifying therapies for neurodegenerative diseases, has announced the enrollment of the first participant in a biomarker

Read more...

Mercury Bio, a biotechnology company based in Santa Fe, NM, has recently become a charter member of the Alliance for mRNA Medicines, a notable global organization dedicated to advancing mRNA and next-generation encoding RNA therapeutics and vaccines

Read more...

GC Biopharma Corp. has announced that the European Medicines Agency granted Orphan Drug Designation to GC1130A, an intracerebroventricular Enzyme Replacement Therapy

Read more...

The RECUR initiative is a collaborative effort involving the American Society for Transplantation and Cellular Therapy, the Association of American Cancer Institutes, and the Association of Community Cancer Centers

Read more...

CGI has recently unveiled a strategic collaboration with Körber to enhance the production processes within the pharmaceutical and life sciences sectors. This partnership aims to integrate

Read more...

Verastem Oncology xhas been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for its investigational RAF/MEK clamp, avutometinib, in combination with Amgen’s KRAS G12C inhibitor,

Read more...

CAR T Global Consultant Inc., a specialized consulting company in the realm of Cell & Gene Therapy, is thrilled to unveil its latest offering—a Contract Cell & Gene Therapy Organization

Read more...

Eisai Co., Ltd. has recently received marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for its injection formulation of the antiepileptic drug Fycompa® in Japan. This approval allows for the use of Fycompa as an alternative therapy

Read more...

Compass Pathways plc and Hackensack Meridian Health have recently entered into a research collaboration agreement to enhance the design of the delivery model for investigational

Read more...

BIOSENIC, a clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, have announced the signing of a binding

Read more...

WuXi Biologics , a globally recognized Contract Research, Development, and Manufacturing Organization, has recently inked a research service agreement

Read more...

Xcell Biosciences, Inc, a company specializing in platform technology for cell and gene therapy applications, has recently announced a collaboration with ElevateBio, LLC. The partnership aims

Read more...

Walden Biosciences, Inc, a private biotechnology company concentrating on revolutionizing the treatment of kidney disease

Read more...

SELLAS Life Sciences Group, Inc. has been granted Fast Track Designation by the U.S. Food and Drug Administration for its CDK9 inhibitor, SLS009, targeted at treating relapsed/refractory

Read more...

Biocytogen Pharmaceuticals Co., Ltd, a global biotech firm focused on groundbreaking antibody therapeutics, has revealed an Exclusive Option and License Agreement

Read more...

The Menarini Group, a prominent pharmaceutical and diagnostics company, together with its subsidiary Stemline Therapeutics, and Insilico Medicine, a biotechnology company utilizing artificial intelligence

Read more...

Illumina Inc. has recently forged a partnership with Janssen Research & Development, LLC to advance the development of Illumina's unique molecular residual disease assay.

Read more...

Omniose, a preclinical biotechnology company, has recently revealed an exclusive collaboration agreement with AstraZeneca to investigate potential vaccines

Read more...

Turbine, a notable biological simulation company specializing in the creation of a platform for simulating human biology in silico, has recently disclosed a collaboration with AstraZeneca, a global biopharmaceutical company

Read more...

Merck, a prominent science and technology company, has recently entered into a licensing agreement with Inspirna, Inc. based in New York, NY, for ompenaclid, an innovative oral inhibitor targeting

Read more...

INOVIO, a biotechnology company specializing in DNA medicines for HPV-associated diseases, cancer, and infectious diseases, recently disclosed a clinical collaboration and supply agreement with Coherus BioSciences.

Read more...

AC Immune SA has released a positive update on its active immunotherapy programs, revealing that three Phase 2 trials are advancing towards significant clinical milestones in 2024. Dr. Andrea Pfeifer,

Read more...

Elektrofi, Inc., a company specializing in biopharmaceutical formulation technology, has recently unveiled a global research collaboration and licensing agreement with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson

Read more...

Avenue Therapeutics, Inc, a specialized pharmaceutical company dedicated to advancing therapies for neurologic diseases, has successfully enrolled all participants in the Phase 1b/2a clinical trial of AJ201

Read more...

Windtree Therapeutics, Inc, a biotechnology company specializing in advanced interventions for critical cardiovascular disorders, has announced novel preclinical data on its lead product candidate, istaroxime,

Read more...

ANGLE plc, a prominent player in liquid biopsy technology focused on circulating tumor cell diagnostics for research, drug development, and clinical oncology, has recently entered into a noteworthy agreement with Eisai Inc

Read more...

Cyclo Therapeutics, Inc.and Applied Molecular Transport Inc. have successfully concluded their merger, an all-stock transaction that unites the two biotechnology companies.

Read more...

Scilex Holding Company is a company dedicated to acquiring, developing, and commercializing non-opioid pain management products for both acute and chronic pain. Today, the company announced the submission

Read more...

Senhwa Biosciences, Inc., a company focused on drug development for oncology, rare diseases, and infectious diseases, has received approval from the Taiwan Food and Drug Administration for its Phase II

Read more...

Virax Biolabs Group Limited has recently entered into a strategic collaboration with the University of Manchester and the Northern Care Alliance Foundation Trust. The partnership

Read more...

Ocelot Bio, a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for complications of end-stage liver disease (ESLD), has received Orphan Drug Designation from the U.S

Read more...

Bio-Techne Corporation has recently submitted a Drug Master File to the U.S. Food and Drug Administration for its ExCellerate™ GMP iPSC Expansion Medium,

Read more...

IGC Pharma, Inc., a clinical-stage pharmaceutical company, has received a Granting Office Action from the Divisional Direction of Patents, Mexico, for its Alzheimer's disease treatment

Read more...

Nectin Therapeutics Ltd. recently announced progress in its Phase 1 clinical trial of NTX1088, a novel targeted immunotherapy designed to overcome resistance to existing immune oncology treatments.

Read more...

Avstera Therapeutics Corp has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for AVS100, a novel oral HDAC6

Read more...

Replay, a genome writing company specializing in reprogramming biology through the design and delivery of large DNA, has partnered with Miltenyi Biotec

Read more...

QPS Holdings, a global contract research organization (CRO) that provides drug discovery, preclinical research, bioanalysis, clinical trials, and clinical research services,

Read more...

Mission Therapeutics has achieved a significant milestone as the US Food and Drug Administration has granted approval for its Investigational New Drug application for MTX652

Read more...

Nerviano Medical Sciences S.r.l., a clinical-stage biotechnology company within the NMS group, recently announced a licensing agreement with Italfarmaco S.p.A.

Read more...

Amgen has reported that the U.S. Food and Drug Administration has accepted its Biologics License Application for tarlatamab and granted Priority Review. Tarlatamab

Read more...

Inductive Bio, a tech company specializing in machine learning, has come out of stealth mode with $4.3 million in funding. The seed round was led by Andreessen Horowitz

Read more...

Eisai Co., Ltd. and Biogen Inc. have jointly announced the upcoming launch of the humanized anti-soluble aggregated amyloid-beta monoclonal antibody, "LEQEMBI Intravenous Infusion"

Read more...

GigaGen Inc., a biotechnology company specializing in the development of innovative antibody drugs for immune deficiencies, infectious diseases, and checkpoint-resistant cancers, has received approval

Read more...

Petros Pharmaceuticals, Inc. has disclosed a strategic partnership with Idea Evolver, a technology platform specializing in Rx-to-OTC switches and digital pharmaceutical launch solutions.

Read more...

Ferring Pharmaceuticals and PharmaBiome, a microbiome translation company based in Zürich, have jointly announced a collaborative research and development

Read more...

Glycotope GmbH and Evotec SE have recently entered into a collaborative agreement to integrate Glycotope's antibodies with Evotec's immune cell engager platform for the development

Read more...

Astellas Pharma US, Inc. has obtained approval from the U.S. Food and Drug Administration for the use of CRESEMBA®, an azole antifungal drug, in treating invasive aspergillosis

Read more...

SpyBiotech, a leading biotechnology company known for its groundbreaking vaccine platform technology targeting infectious diseases, cancer, and chronic conditions, has marked a significant achievement

Read more...

ArteraAI, a developer specializing in multimodal artificial intelligence (MMAI) predictive and prognostic cancer tools, has announced a strategic collaborative agreement

Read more...

Novartis has received FDA approval for Fabhalta® (iptacopan), making it the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria. Fabhalta, a Factor B inhibitor, controls red blood

Read more...

Taiwan Bio and TRACT Therapeutics have recently announced a strategic partnership aimed at advancing cellular therapy to transform the prevention of allograft rejection in solid organ transplants.

Read more...

BioInvent International AB, publicly traded on Nasdaq Stockholm with the ticker symbol BINV, is a biotech company specializing in the exploration and development of innovative immune-modulatory antibodies for cancer

Read more...

Petros Pharmaceuticals, Inc. is excited to announce its collaboration with Idea Evolver, a leading technology platform specializing in Rx-to-OTC switches and digital pharmaceutical

Read more...

BridgeBio Pharma, Inc. has achieved a significant milestone by filing a New Drug Application with the U.S. Food and Drug Administration for acoramidis, a potential treatment for ATTR-CM

Read more...

Exelixis, Inc. and Arcus Biosciences have recently announced a collaboration for the clinical trial named STELLAR-009. This trial, a phase 1b/2 investigation,

Read more...

Carmot Therapeutics Inc, a biotechnology firm in the clinical stage dedicated to developing transformative therapeutics for individuals facing metabolic diseases like obesity and diabetes

Read more...

Ambio, Inc., a pioneering biotechnology company specializing in the development of innovative peptide drugs, biosimilars, bioequivalents, and other intricate generic drugs, announced today that the U.S. Food and Drug Administration

Read more...

Fujirebio Holdings, Inc. and Sysmex Corporation jointly announced today the expansion of their contract development and manufacturing services

Read more...

SciNeuro Pharmaceuticals, a biotech company in the clinical stage, has successfully concluded dosing in its Phase 1 study, focusing on the development of treatments for neurodegenerative diseases

Read more...

ASC Therapeutics, a privately-owned biopharmaceutical company specializing in the development of in-vivo gene replacement, gene editing, and allogeneic cell therapies

Read more...

REGENXBIO Inc. celebrated a major milestone as the first patient received RGX-202 at dose level 2 in the Phase I/II AFFINITY DUCHENNE® trial. This trial is investigating RGX-202, a novel

Read more...

Ensysce Biosciences, Inc. and OncoZenge AB have recently announced the signing of a letter of intent (LOI) to explore a strategic collaboration for the accelerated

Read more...

TOLREMO therapeutics AG has announced the initiation of its Phase 1 clinical trial, with the dosing of the first patient taking place. This trial is designed to assess the safety, tolerability,

Read more...

Recce Pharmaceuticals Limited has officially received approval from the Canadian Patent Office for a new patent titled "Process for Preparation of Biologically Active Copolymer

Read more...

Arcturus Therapeutics Holdings Inc. has recently announced that the U.S. Food and Drug Administration granted Orphan Drug Designation for ARCT-032, the company's product candidate for treating cystic fibrosis

Read more...

Hemogenyx Pharmaceuticals plc has made a noteworthy expansion in the potential applications of its Chimeric Bait Receptor platform. Initially designed for treating viral diseases

Read more...

Simcere Pharmaceutical Group Limited recently finalized an exclusive license and collaboration agreement with Connect Biopharma HongKong Limited concerning Rademikibart, an innovative IL-4Rα monoclonal antibody

Read more...

Immutep Limited has expanded the INSIGHT-003 trial to include four sites across Germany, including the University Clinic of Ruhr Universität Bochum and the Lung Clinic Cologne-Merheim

Read more...

Immutep Limited has expanded the INSIGHT-003 trial to include four sites across Germany, including the University Clinic of Ruhr Universität Bochum and the Lung Clinic Cologne-Merheim.

Read more...

BeiGene, Ltd. and Ensem Therapeutics, Inc. have disclosed a strategic collaboration, wherein BeiGene will acquire an exclusive global license for an Investigational New Drug

Read more...

MIRA Pharmaceuticals, Inc., has unveiled a strategic collaboration with MIRALOGX, LLC, an intellectual property holding company established by MIRA's founder. This partnership grants MIRA exclusive development

Read more...

HOOKIPA Pharma Inc, a company focused on developing immunotherapeutics using its proprietary arenavirus platform, has received FDA clearance for its Investigational New Drug

Read more...

Avistone Biotechnology Co. Ltd. has recently gained conditional approval from the National Medical Products Administration to market Vebreltinib, a precision oncology therapeutic,

Read more...

Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company focused on precision medicine for Alzheimer's and other age-related diseases, has announced that the U.S. Food and Drug Administration

Read more...

Axxam S.p.A. and Momentum Biotechnologies have recently formed a partnership to deliver innovative drug discovery solutions for clients in the biotechnology and pharmaceutical industries. The collaboration involves making Axxam's

Read more...

Athira Pharma, Inc., recently unveiled promising preclinical data on fosgonimeton, a potential breakthrough in the treatment of Alzheimer's disease and other neurodegenerative conditions.

Read more...

Ardelyx, Inc., is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines to address unmet medical needs. The company recently announced that the U.S. Food and Drug Administration

Read more...

Alvotech and JAMP Pharma Group have jointly announced that Health Canada has granted marketing authorization to JAMP Pharma for AVT04, a biotech analogue of Stelara (ustekinumab) developed by Alvotech.

Read more...

Cerevance, a company dedicated to advancing precision therapeutics for central nervous system disorders, has recently initiated the Phase 2 clinical study of CVN424 in individuals diagnosed with early-stage Parkinson's disease

Read more...

Legend Biotech Corporation has recently announced a significant development - its wholly-owned subsidiary, Legend Biotech Ireland Limited, has entered into an exclusive global license agreement with Novartis Pharma AG

Read more...

Alvotech and STADA Arzneimittel have received a favorable opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency

Read more...

Andelyn Biosciences, Inc., a forward-thinking Contract Development and Manufacturing Organization

Read more...

BioRay Pharmaceutical Co. has commenced the Phase I clinical trial for BRY812, an innovative antibody-drug conjugate targeting LIV-1, a zinc transporter associated with cell growth in advanced malignancies.

Read more...

LAPIX Therapeutics, Inc., a biopharmaceutical company dedicated to the development of innovative orally deliverable therapies for autoimmune diseases, has initiated the Phase 1 clinical trial for its LPX-TI641 therapy

Read more...

BostonGene, a leading provider of AI-driven solutions for molecular and immune profiling, has announced a collaboration with LegoChem Biosciences, Inc. (LCB), a clinical-stage biopharmaceutical company specializing in the development

Read more...

Acorda Therapeutics, Inc, has made an announcement regarding new regulatory submissions for the approval of INBRIJA® (levodopa inhalation powder) in six Latin American countries through its partner,

Read more...

Halozyme Therapeutics, Inc, has recently announced a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals. This partnership grants Acumen access to Halozyme's ENHANZE® drug delivery technology,

Read more...

BioCina Pty Ltd., a globally renowned biologics contract development and manufacturing organization, has recently announced an expanded partnership with GPN Vaccines Ltd. GPN Vaccines is a biotechnology company focused on developing Gamma-PN™

Read more...

Immutep Limited has released new biomarker data from its Phase II trial, in which they investigated eftilagimod alpha, a soluble LAG-3 protein and first-in-class MHC Class II agonist administered subcutaneously. This trial examined efti in conjunction

Read more...

Regulus Therapeutics Inc. is a biopharmaceutical company that focuses on the discovery and development of innovative medicines targeting microRNAs. The company, also known as Regulus,

Read more...

Bayer and the Broad Institute of MIT and Harvard recently announced the extension of their research partnership for another five years, following a decade of successful collaboration. This renewed agreement

Read more...

Kyverna Therapeutics, a clinical-stage company specializing in cell therapy and focused on developing innovative treatments for severe autoimmune diseases, has recently entered into a multi-year research funding agreement

Read more...

Prelude Therapeutics Incorporated and AbCellera have recently unveiled a multi-year, multi-program partnership aimed at the exploration, advancement, and market launch of innovative treatments for cancer patients.

Read more...

Chimeric Therapeutics, an Australian leader in cell therapy, announced today that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for CHM 2101, the company's first-in-class CDH17 CAR T cell therapy

Read more...

Oncoinvent AS, a company in the clinical stage focused on advancing alpha emitter therapy for various solid cancers, has officially received approval from the U.S. Food and Drug Administration for its Investigational New Drug

Read more...

Transpire Bio's commitment to Florida and the establishment of a biomanufacturing workforce in Weston. She envisioned this move as a potential opportunity to position South Florida at the forefront of the life sciences industry.

Read more...

AnHeart Therapeutics, a global clinical-stage biopharmaceutical company, has recently established an exclusive license agreement with Nippon Kayaku Co., Ltd for the marketing and distribution of their lead investigational therapy.

Read more...

Biophytis SA, a biotechnology company in the clinical development stage listed on Nasdaq CM and Euronext Growth Paris, specializes in the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving

Read more...

Oncternal Therapeutics, Inc, is a clinical-stage biopharmaceutical company dedicated to developing novel oncology treatments. They recently announced that the U.S. Food and Drug Administration has granted Fast Track designation for ONCT-534.

Read more...

Simbec-Orion, a mid-sized Contract Research Organization, and biotx.ai, a company specializing in AI-powered causal modeling for drug development, have officially revealed their strategic partnership

Read more...

ReHeva Biosciences, an innovative biopharmaceutical startup, is thrilled to announce the successful completion of its Phase I Safety Trial for its groundbreaking drug, RH324. This achievement represents a major milestone in the company's

Read more...

Turbine, a computational biology company specializing in empirically validated in silico cell simulations for guiding biopharmaceutical research and development, has announced a collaborative partnership

Read more...

Elektrofi, Inc., a biopharmaceutical formulation technology company specializing in strategic partnerships to revolutionize the delivery of biologic therapies, has announced a multi-target research collaboration and license agreement with Eli Lilly

Read more...

Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored immunotherapies for cancer treatment, has received approval for its investigational new drug application from the U.S. Food & Drug Administration

Read more...

Kiromic BioPharma, Inc. has made a significant announcement regarding its clinical initiatives. The company, a pioneer in the field of biotherapeutics, is utilizing its exclusive DIAMOND® artificial intelligence

Read more...

Iksuda Therapeutics, a company specializing in the development of innovative antibody drug conjugates with enhanced tumor specificity, has announced a significant milestone in its clinical trials. The first patient has successfully completed the initial treatment cycle of IKS014, an antibody-drug

Read more...

Amgen, a company listed on NASDAQ under the symbol AMGN, has unveiled the findings from the global Phase 2 DeLLphi-301 study. This study assessed the efficacy of tarlatamab

Read more...

Rise Therapeutics, a biotechnology company specializing in the development of novel oral immunotherapeutics, has announced that the U.S. Food and Drug Administration has approved its investigational new drug

Read more...

Qnovia, Inc., a pharmaceutical company specializing in the development of inhaled therapeutic products across various medical fields, has announced a collaborative effort with the University of Virginia to advance innovative inhaled drug candidates

Read more...

Mablink Bioscience, a biotechnology company that focuses on advancing next-generation antibody-drug conjugates through its proprietary PSARLink™ platform, has announced its acquisition by Eli Lilly and Company.

Read more...

Vaxcyte, Inc, has announced that the U.S. Food and Drug Administration has granted approval for the company's Investigational New Drug application for VAX-31, a 31-valent pneumococcal conjugate vaccine

Read more...

Bolt Biotherapeutics has initiated its first-in-human Phase 1/2 clinical trial by dosing the inaugural patient with BDC-3042, a monoclonal antibody designed to repolarize tumor-associated macrophages (TAMs) for the purpose of combating cancer

Read more...

SOTIO, a clinical-stage immuno-oncology company owned by PPF Group, has recently entered into a license and option agreement with Synaffix B.V., a subsidiary of Lonza, to develop next-generation antibody-drug

Read more...

Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, and INGENIA Therapeutics, a preclinical-stage biotech company

Read more...

Mundipharma and Cidara Therapeutics (Nasdaq: CDTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has

Read more...

AGC Biologics , a leading global biopharmaceutical contract developer and manufacturer (CDMO), today announced the completion of facility expansion for its new plasmid DNA (pDNA)

Read more...

Cyrano Therapeutics, Inc., a regenerative medicine company pioneering the development of treatments for smell loss, announced today that it has commenced enrollment in the Phase 2

Read more...

Lucy Therapeutics (LucyTx) has obtained additional funding from the International Rett Syndrome Foundation (IRSF) to support innovative treatments for individuals, both children and adults, grappling with Rett syndrome. This funding will also contribute to the expansion of LucyTx's pioneering treatment platform.

Read more...

Eurofins CDMO Alphora Inc. announces that it has received its Health Canada Cannabis Drug License issued within the Cannabis Act and Cannabis Regulations for its Oakville, Ontario operations in September 2023. This compliments the Institutional Research License obtained through Health Canada in June 2021 for its Mississauga development site and a Standard Processing License obtained for the Oakville, Ontario manufacturing operation in May 2022.

Read more...

Gritgen Therapeutics Co., Ltd., a biotechnology company specializing in the discovery and development of cutting-edge gene therapy products, is pleased to announce the successful validation and official commencement of operations at its commercial Good Manufacturing Practices (GMP) facility located in Suzhou Industrial Park.

Read more...

Fujirebio Holdings, Inc. (Headquarters: Minato-ku, Tokyo; President & CEO: Goki Ishikawa) and Sysmex Corporation (Headquarters: Kobe, Japan; President: Kaoru Asano) jointly announce a Basic Agreement on Business Collaboration to foster a multifaceted partnership encompassing research and development, production, clinical development, and sales-marketing in the field of immunoassay.

Read more...

Thermo Fisher Scientific, the global leader in scientific services, has announced an expansion of its manufacturing capacity in St. Louis, aimed at supporting the production of biologic therapies for a wide range of diseases, including cancer, autoimmune conditions, and rare genetic disorders.

Read more...

Wheeler Bio, a contract development and manufacturing organization (CDMO) specializing in next-gen protein therapeutics, is pleased to announce the inauguration of its cutting-edge Current Good Manufacturing Practices (CGMP) drug substance facility located in the Ziggurat building (Echo Investment Capital) in Oklahoma City, OK.

Read more...

GC Biopharma Corp. has officially announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to its drug candidate, GC1126A, for the treatment of Thrombotic Thrombocytopenic Purpura (TTP). This significant development was finalized on September 27.

Read more...

Shasqi, a clinical-stage biotech company specializing in improving the effectiveness of cancer drugs using click chemistry, has announced an expansion of its ongoing research collaboration with Johnson & Johnson Enterprise Innovation Inc.

Read more...

DelNova has announced a partnership with Pace® Life Sciences to serve as its contract development and manufacturing organization (CDMO). This collaboration will enable DelNova to advance the clinical development of its lead candidate

Read more...

BostonGene, a prominent provider of AI-based molecular and immune profiling solutions, has announced a master agreement with Johns Hopkins University School of Medicine (JHUSOM) to collaborate on multiple clinical research projects. This partnership enables BostonGene and JHUSOM to further explore and validate innovative precision medicine approaches.

Read more...

Meitheal Pharmaceuticals, Inc., a fully integrated generic injectables company headquartered in Chicago, has expanded its portfolio of generic injectable products through an asset purchase agreement made by its parent company, Hong Kong King-Friend Industry Co., (HKF). This agreement has increased Meitheal's total portfolio of generic injectables to include 82 products.

Read more...

Natera, a global leader in cell-free DNA testing, has submitted the first module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Signatera. Signatera is Natera's personalized and tumor-informed molecular residual disease (MRD) test,

Read more...

Advent International and Warburg Pincus have successfully completed their acquisition of Baxter International Inc.'s BioPharma Solutions (BPS) business.

Read more...

Promontory Therapeutics Inc., a clinical-stage biotechnology company specializing in immunogenic small molecule approaches in oncology, has achieved the distinction of being the first international company to gain membership in the Paris-Saclay Cancer Center (PSCC).

Read more...

Oragenics, Inc. (NYSE American: OGEN) has entered into a significant partnership with Lantern Bioworks, marked by the formalization of a materials transfer agreement. This collaboration follows rigorous testing and validation of biological samples from Oragenics.

Read more...

Orsini Specialty Pharmacy has been chosen by Amicus Therapeutics as the provider for Pombiliti™ (cipaglucosidase alfa-atga) and Opfolda™ (miglustat), a combination treatment approved for specific patients with late-onset Pompe disease.

Read more...

Mabwell, an innovative biopharmaceutical company with an entire industry chain, has announced that the first patient has been dosed in a phase Ib/II trial of its novel Nectin-4 targeting ADC (R&D code: 9MW2821) in combination with a PD-1 inhibitor for the treatment of locally advanced or metastatic urothelial carcinoma.

Read more...

Everest Medicines has received approval from the Taiwan Food and Drug Administration (TFDA) for its New Drug Application (NDA) for XERAVA® (eravacycline).

Read more...

Calliditas Therapeutics AB has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its drug setanaxib for the treatment of Alport syndrome.

Read more...

Nexus Pharmaceuticals, LLC has announced its receipt of approval from the U.S. Food and Drug Administration (FDA) for Fluorescein Injection, USP. Usman Ahmed, President and Chief Executive Officer of Nexus Pharmaceuticals, expressed enthusiasm about this FDA approval, stating

Read more...

Chrysalis BioTherapeutics, Inc. has received permission from the U.S. Food and Drug Administration (FDA) to commence human clinical trials focused on treating acute lung failure. With the approval of its Investigational New Drug (IND) Application

Read more...

AcuraStem, a biotechnology company focused on developing treatments for neurodegenerative diseases, has entered into a licensing agreement with Takeda to collaborate on the development and commercialization of AcuraStem's PIKFYVE targeted therapeutics, including AS-202, an antisense oligonucleotide (ASO) designed for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Read more...

Chime Biologics, a prominent Contract Development and Manufacturing Organization (CDMO) specializing in biologics, has entered into a strategic cooperation agreement with Kings Pharm. Under this agreement, Chime Biologics will utilize its extensive expertise in biosimilar projects to provide Kings Pharm

Read more...

The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR)

Read more...

Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 monoclonal antibody

Read more...

Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical firm specializing in innovative inhaled therapies for serious pulmonary and central nervous system disorders, has announced that the U.S. Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application for PUR3100 and issued a study may proceed letter.

Read more...

Brain diagnostics innovator BrainScope has secured new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) as part of its ongoing Series B equity financing round. This investment will support the development of an Artificial Intelligence / Machine Learning-derived brain-activity-based biomarker aimed at predicting the future onset of Alzheimer’s disease.

Read more...

Unravel Biosciences, Inc. (referred to as "Unravel") has unveiled a pioneering initiative known as rareSHIFT™, aimed at expediting patient-centric drug discovery and translation with unmatched speed.

Read more...

ST Pharm recently celebrated the completion of its groundbreaking ceremony, marking a significant stride in its efforts to expand its oligonucleotide manufacturing capacity and capabilities.

Read more...

Following FDA authorization and CDC recommendation, Rite Aid (NYSE: RAD) has announced that eligible customers can now schedule appointments to receive the updated COVID-19 (2023-2024) vaccines at its locations and Bartell Drugs locations in the Pacific Northwest. Appointments are available starting on Friday, September 22.

Read more...

Daiichi Sankyo (TSE: 4568) has announced that quizartinib has received a favorable recommendation for approval in the European Union (EU). This approval is for its use in combination with standard cytarabine and anthracycline induction, as well as standard cytarabine consolidation chemotherapy.

Read more...

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF), a North American biopharmaceutical company dedicated to the development of patient-centric medications for orphan and rare diseases, has announced a significant update.

Read more...

Acticor Biotech (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biopharmaceutical company developing glenzocimab, an innovative drug for treating cardiovascular emergencies, has announced its refined development plan for Acute Ischemic Stroke (AIS) aimed at obtaining glenzocimab's registration in Europe and the United States.

Read more...

Biosyngen Pte Ltd (referred to as "Biosyngen") has announced that the U.S. FDA has granted clearance for the Investigational New Drug (IND) application for the Phase I/II clinical trial of BRL03.

Read more...

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company dedicated to discovering and developing targeted therapeutics, has initiated a Phase 1 monotherapy expansion in its first-in-human clinical trial assessing IDE161 (NCT 05787587).

Read more...

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotechnology company specializing in novel antibody therapeutics, has entered into a significant agreement with Myricx Bio, a British biotechnology company focused on creating a new class of cytotoxic payloads specifically designed for antibody-drug conjugates (ADCs).

Read more...

Mabwell (Stock Code: 688062.SH) is an innovative biopharmaceutical company with a comprehensive presence in the pharmaceutical industry value chain. The company is dedicated to providing more effective and accessible therapies and innovative medicines to meet global medical needs.

Read more...

Verily, a subsidiary of Alphabet specializing in precision health technology, and Kyverna Therapeutics, a clinical-stage cell therapy company focused on developing therapies for autoimmune diseases, have announced a multi-year collaboration aimed at identifying novel biomarkers and innovating clinical trial design and execution.

Read more...

Nanostics Inc., a precision health company specializing in diagnostic tests developed with its ClarityDX® platform technology, has announced that the College of Physicians and Surgeons of Alberta (CPSA) has granted provisional accreditation to Nanostics Clinical Laboratory in Edmonton, Alberta, Canada.

Read more...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, has unveiled new data showcasing the potent in vitro activity of NRX-101 (D-cycloserine + lurasidone) against reference strains of urinary tract pathogens known to cause complicated urinary tract infections (cUTIs)

Read more...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) has announced its receipt of Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for calcium gluconate in sodium chloride injection, specifically in 1000 mg/50 mL and 2000 mg/100 mL formulations. This injectable product is currently listed on the U.S. FDA shortage product list.

Read more...

PsychoGenics Inc. (PsychoGenics) and Collaborations Pharmaceuticals, Inc. (CPI) are excited to announce the receipt of a $1 million Phase I Small Business Innovation Research (SBIR) grant. This grant represents a significant step forward in their collaboration, which seeks to utilize their combined AI capabilities to develop innovative drugs for mental health disorders.

Read more...

XtalPi, a leader in AI-driven drug discovery, and Parthenon Therapeutics, a biotech firm focused on reshaping the tumor microenvironment, have announced a collaboration to develop new therapeutic antibodies for treating solid tumors.

Read more...

Korean clinical trial sample analysis company, GCCL, announced on September 5th that it has implemented the Lab Information Management System (LIMS) for the first time in the sample analysis industry.

Read more...

Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) have jointly announced the positive results from the Phase 3 innovaTV 301 global trial, which focused on recurrent or metastatic cervical cancer patients with disease progression after initial therapy.

Read more...

INtRON Biotechnology, a biotech company, has announced a formal contract between its New Drug Part and the U.S. Army DEVCOM (U.S. Army Combat Capabilities Development Command) International Technology Center Indo-Pacific and Soldier Center. The contract aims to collaborate on the development of bacteriophages for combatting Uropathogenic Escherichia coli (UPEC) infections.

Read more...

Amgen (NASDAQ: AMGN) and Horizon Therapeutics plc (NASDAQ: HZNP) have jointly announced the execution of a consent order agreement with the Federal Trade Commission (FTC) as a resolution to the ongoing FTC administrative lawsuit. This agreement paves the way for the final steps toward completing Amgen's acquisition of Horizon.

Read more...

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKEX: 02315) is pleased to announce the formal establishment of two significant business divisions, each representing distinct aspects of the company's comprehensive product, service, and asset portfolio.

Read more...

Twist Bioscience Corporation (NASDAQ: TWST) has unveiled a significant drug discovery partnership with Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") aimed at the development of novel antibodies for treating autoimmune diseases.

Read more...

Serina Therapeutics, Inc. (referred to as "Serina"), a clinical-stage biotechnology firm dedicated to developing therapies for Parkinson's Disease and other neurological disorders, has entered into a merger agreement with AgeX Therapeutics, Inc. (NYSE American: AGE), a publicly traded biotechnology company, on August 29, 2023.

Read more...

Cybin Inc. a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, and Small

Read more...

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company dedicated to advancing cancer treatment and prevention, has initiated the treatment of the third participant in collaboration with Moffitt Cancer Center as part of an ongoing clinical trial for its innovative chimeric antigen receptor T-cell (CAR-T) therapy designed for ovarian cancer.

Read more...

Allucent, a prominent global mid-sized clinical research organization (CRO), has been designated by the Biomedical Advanced Research and Development Authority

Read more...

Zhiyi Biotech has announced the initiation of the U.S. Phase 1 clinical trial for their innovative product SK10, which is aimed at addressing Chemotherapy-induced Diarrhea (CID). The trial marks a significant milestone as the first three subjects have been successfully dosed. SK10 is a heat-killed Bacteroides fragilis product developed by Zhiyi Biotech.

Read more...

Altogen Labs, a preclinical Contract Research Organization (CRO) laboratory, has announced the successful validation of a comprehensive array of 10 lung cancer xenograft models.

Read more...

MapLight Therapeutics, a clinical-stage biopharmaceutical company specializing in the development of targeted therapeutics for brain disorders, has successfully completed a second Phase 1 clinical trial assessing the safety and efficacy of ML-007, a novel M1/M4 muscarinic receptor agonist.

Read more...

Everest Medicines, a biopharmaceutical company dedicated to developing, manufacturing, and commercializing innovative medicines and vaccines, has announced that the Pharmaceutical Administration Bureau of the Macao Special Administrative Region, China, has accepted its New Drug Application (NDA) for Nefecon®.

Read more...

SimBioSys, a pioneering TechBio company leveraging Artificial Intelligence (AI), spatial biophysics, and data science to redefine precision medicine and combat cancer, proudly announces its role as one of the founding members of the CancerX initiative.

Read more...

AGC Biologics, a prominent global biopharmaceutical contract development and manufacturing organization (CDMO), has unveiled the expansion of its Longmont, Colorado facility with the addition of three state-of-the-art Grade B cell therapy manufacturing facilities.

Read more...

Paradigm Therapeutics Inc., a biopharmaceutical company, has successfully finalized the acquisition of the global rights for SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. The specifics of the agreement have not been publicly disclosed.

Read more...

LEO Pharma has officially announced a strategic move to acquire Timber Pharmaceuticals, Inc., a company listed on the NYSE American under the ticker symbol TMBR.

Read more...

Enveric Biosciences (NASDAQ: ENVB), a biotech firm dedicated to pioneering innovative neuroplastogenic small-molecule therapeutics aimed at addressing anxiety, depression, and addiction disorders, has recently achieved a significant milestone.

Read more...

Everest Medicines (HKEX: 1952.HK) has announced that the U.S. Food and Drug Administration (FDA) has accepted the submission for the supplemental New Drug Application (sNDA) for Nefecon® from its partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) and has granted Priority Review.

Read more...

Reykjavik-based pharmaceutical discovery company, 3Z, has partnered with causal AI firm biotx.ai, based in Germany and the US, with the aim of revolutionizing the development of drugs for ADHD. Through the integration of advanced AI modeling techniques, this collaboration seeks to bridge the gap between animal-based studies and human clinical trials, facilitating a more precise and efficient translation of promising therapies.

Read more...

Response Pharmaceuticals, Inc. today announced the successful completion of its Phase 1B clinical trial for the company's lead drug candidate, RDX-002, a first-in-class inhibitor of intestinal

Read more...

Neurophth Therapeutics, Inc. announced today that the first patient has been dosed in the international multi-region, multi-center Phase I/II clinical trial for the treatment of Leber hereditary

Read more...

Boston Immune Technologies and Therapeutics, Inc. (BITT), a biotechnology company in the clinical stage, has announced that its Investigational New Drug application (IND) for BITT2101 (anti-TNFR2), a novel tumor necrosis factor superfamily receptor (TNFSR) antagonist antibody

Read more...

CervoMed Inc. (formerly Diffusion Pharmaceuticals Inc.) (NASDAQ: CRVO), now a clinical-stage company focused on developing treatments for degenerative brain diseases, has successfully completed its previously announced merger with EIP Pharma Inc.

Read more...

Tigermed (300347.SZ/3347.HK), a prominent global Contract Research Organization (CRO) offering comprehensive research and development solutions for the biopharmaceutical and medical device sectors, has officially inaugurated its International Headquarters in Hong Kong.

Read more...

We are pleased to announce a fresh collaboration with Asahi Kasei Pharma Corporation aimed at producing clinical drug substance for antibody-based therapies.

Read more...

Impilo Therapeutics, Inc. (referred to as "Impilo"), a privately-owned enterprise specializing in drug discovery and development, has officially launched its operations with a core mission to facilitate the effective utilization of nucleic acid-based medicines for the treatment of solid tumor cancers.

Read more...

Nexus Pharmaceuticals has announced its receipt of approval from the U.S. Food and Drug Administration (FDA) for Potassium Chloride for Injection Concentrate, USP in 10mL and 20mL Single-Dose Vials.

Read more...

Asieris Pharmaceuticals (688176) is a prominent global biopharmaceutical firm specializing in the research, development, and commercialization of novel drugs targeting genitourinary tumors and related ailments.

Read more...

Antengene Corporation Limited (SEHK: 6996.HK), a prominent global biopharmaceutical company focused on innovative therapies in hematology and oncology

Read more...

Rising Pharmaceuticals, a subsidiary of Rising Pharma Holdings Inc., has announced the approval, launch, and immediate availability of Edetate calcium disodium injection, addressing a critical shortage of this vital therapy in the United States.

Read more...

Brenntag, a prominent global player in the distribution of chemicals and ingredients, has announced a strategic collaboration with audit provider Qualifyze.

Read more...

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), a pioneering clinical stage biopharmaceutical company dedicated to advancing innovative treatments for brain health disorders, has announced a strategic license agreement with Catalent

Read more...

Roche today announced the expansion of their Global Business Partnership Agreement with Sysmex. As part of the renewed framework, the companies strengthen their commitment

Read more...

NeuroBo Pharmaceuticals, Inc. a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that it has entered into a term sheet with MThera

Read more...

Tyra Biosciences, Inc.a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor

Read more...

Alpenglow Biosciences has been awarded a $1.6M grant to develop artificial intelligence (AI) enabled smart microscopy using its patented multi-resolution 3Di platform for 3D spatial biology.

Read more...

Harrow a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application for VIGAMOX® 0.5%, a fluoroquinolone antibiotic

Read more...

Astellas Pharma Inc. today announced that the Center for Drug Evaluation of the China National Medical Products Administration (NMPA) has accepted the Biologics License Application

Read more...

Ionis Pharmaceuticals, Inc. today announced it has expanded its existing collaboration with AstraZeneca to include exclusive rights for AstraZeneca to commercialize eplontersen in Latin

Read more...

Biosion USA, Inc. a global clinical-stage R&D biotechnology company, today announced the phase 2 study initiation for the evaluation of BSI-045B, an anti-TLSP mAb, in the treatment of atopic dermatitis.

Read more...

Today, the U.S. Food and Drug Administration approved RiVive, 3 milligram (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription use for the emergency treatment of known or suspected opioid overdose.

Read more...

KORU Medical Systems, Inc., a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions, today announced an agreement with a biopharmaceutical company to validate

Read more...

WuXi Vaccines, a leading global vaccine CDMO (Contract Development and Manufacturing Organization), today announced the successful GMP release of its CHO cell-based drug substance (DS) manufacturing facility located in Suzhou

Read more...

Bio-Rad Laboratories, Inc. and QIAGEN N.V., today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating

Read more...

Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today XERAVA

Read more...

Clinical stage Australian biotech company HaemaLogiX Ltd is pleased to announce it has entered into a co-development agreement with the world leading Peter MacCallum Cancer Centre

Read more...

InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company has received approval to conduct

Read more...

Astellas Pharma Inc. and PeptiDream Inc.today announced a research collaboration and license agreement to discover novel protein degraders for two targets selected by Astellas. Under the

Read more...

Cybin Inc.company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that its Phase 2 trial

Read more...

ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biological therapeutics, announced

Read more...

BeiGene a global biotechnology company, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion

Read more...

SunHo BioPharmaceutical Co., Ltd.a clinical-stage leading biopharmaceutical company in immunocytokines with full-set of capabilities from discovery to commercialization, announced

Read more...

MaaT Pharma, a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM dedicated to improving survival outcomes for patients

Read more...

Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases. Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer.

Read more...

Approved for Public Release, Distribution Unlimited — The Defense Advanced Research Projects Agency (DARPA) announced that Ginkgo Bioworks which is building

Read more...

Gannex Pharma Co., Ltd. a wholly-owned company of Ascletis Pharma Inc.announces today the completion of enrollment of 98 patients with primary biliary cholangitis

Read more...

Santen Pharmaceutical Co.,Ltd.announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.

Read more...

Endo International plc announced today that its Par Sterile Products business has begun shipping bivalirudin injection in a ready-to-use 250 mg/50 mL single-use vial. It is the only ready-to-use liquid format of bivalirudin on the market in the U.S.

Read more...

Umitomo Chemical Co., Ltd, one of Japan's leading chemical companies, and Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity,

Read more...

Beckman Coulter Diagnostics, a leader in clinical diagnostics, and Fujirebio, a leader in neurological markers and in vitro diagnostics, announced today the formation of a new

Read more...

Scipher Medicine today announced that it has entered into a multi-disease area collaboration with Ionis Pharmaceuticals. In the collaboration, Ionis is responsible

Read more...

Sangamo Therapeutics, Inc a genomic medicine company, today announced it has signed an evaluation and option agreement with Prevail Therapeutic a wholly owned

Read more...

TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease today announced results from a prespecified analysis of the Phase 3 LUCIDITY

Read more...

Eli Lilly and Company and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.

Read more...

Acadia Pharmaceuticals Inc. today announced that it has expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American

Read more...

KSQ Therapeutics, Inc. a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, announced today

Read more...

Credible, a San Francisco-headquartered, AI-powered ESG Company has onboarded Ajanta Pharma Ltd, a leading global pharmaceutical company to improve its ESG

Read more...

Liminal BioSciences Inc.and Structured Alpha LP a fund managed by Thomvest Asset Management Ltd., today announced that they have entered into a definitive arrangement

Read more...

Bridge Biotherapeutics, a South Korean clinical-stage biotech company developing novel drugs for fibrosis, cancer and inflammation, announced that it has joined PROLIFIC, the Prognostic Lung Fibrosis Consortium, an organization devoted to boosting scientific exploration

Read more...

Redwood Scientific Technologies Inc., a pioneering pharmaceutical company based in New York, is proud to announce the filing of a new patent for its cutting-edge Oral Thin Film (OTF) manufacturing system. The patent showcases Redwood's commitment to revolutionizing

Read more...

Zhejiang Doer Biologics Co., Ltd. a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announced that it has entered into a license agreement with BioNTech SE.

Read more...

Astellas Pharma Inc. and 4D Molecular Therapeutics, Inc. today announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100*

Read more...

Today, the US Food and Drug Administration converted the approval process for Leqembi indicated for the treatment of adult patients with Alzheimer's disease, is on traditional approval after a confirmatory study verified clinical benefit.

Read more...

NS Pharma, Inc. announced today the U.S. Food & Drug Administration has granted Rare Pediatric Disease Designation to NS-089/NCNP-02 (brogidirsen) an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.

Read more...

South Rampart Pharma, Inc. a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that the China National Intellectual

Read more...

Asieris Pharmaceuticals a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related

Read more...

BioArctic AB's partner Eisai announced today that the U.S. Food and Drug Administration, FDA, has approved the supplemental Biologics License Application, sBLA, supporting the traditional

Read more...

Novavax, Inc.a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, has been granted full Marketing Authorization by the European Commission

Read more...

Pheon Therapeutics a leading Antibody-Drug Conjugate specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces an exclusive licence agreement

Read more...

Ascentage Pharma announced today that the company's core product Orebatinib has obtained clinical trial approval from the Center for Drug Evaluation of the National Medical Products

Read more...

Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration has accepted and granted Priority Review for the company’s Biologics License Application for zolbetuximab

Read more...

InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the first psoriasis patient has been dosed in clinical trial

Read more...

Taiho Oncology Europe GmbH and Taiho Pharmaceutical Co., Ltd., announced today that the European Commission has granted conditional marketing authorization for LYTGOBI® monotherapy for the treatment of adult patients with locally advanced or metastatic

Read more...

Amneal Pharmaceuticals, Inc. today announced the launch of its authorized generic for Xyrem®1 oral solution CIII in the United States. Sodium Oxybate oral solution, 0.5 g/mL is a central nervous

Read more...

ARUP Laboratories today announced that the U.S. Food and Drug Administration has approved AAV5 DetectCDx™ as a companion diagnostic to aid in the selection of adult patients eligible for treatment with ROCTAVIAN™ (valoctocogene roxaparvovec-rvox). ROCTAVIAN™, a new gene

Read more...

Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties

Read more...

TME Pharma N.V. a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment, announces a positive clinical update on the survival of first-line glioblastoma patients in the GLORIA expansion arm evaluating NOX-A12,

Read more...

Allecra Therapeutics announced today the submission of a New Drug Application to the U.S. Food and Drug Administration for cefepime/enmetazobactam, an antibiotic combination of the fourth

Read more...

Pharmadule Morimatsu and WuXi Biologics officially entered into a global strategic cooperation for the Singapore CRDMO Center project of WuXi Biologics.

Read more...

Savara Inc. a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that enrollment has been completed for the pivotal Phase 3 IMPALA-2 trial.

Read more...

NephroDI Therapeutics (NephroDI), a pharmaceutical company focusing on concentration disorders of the kidney, announces today it has entered an agreement with The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family

Read more...

Spaulding Clinical, a leading clinical research organization (CRO), is expanding its services to include ADME (absorption, distribution, metabolism, and excretion) clinical trials. This strategic addition further solidifies Spaulding Clinical’s commitment

Read more...

Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company today announced initiation of Part 2 of the RECONNOITER Phase 2 study, evaluating Profervia®, a once-daily novel, oral

Read more...

Virpax® Pharmaceuticals, Inc. a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders

Read more...

Simulations Plus, Inc., a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the acquisition of Immunetrics, Inc. (“Immunetrics”), a modeling and simulation

Read more...

Biolinq Incorporated, a medtech company that is developing novel biosensing technologies, has signed an exclusive license agreement with Taisho Pharmaceutical Co., Ltd., to commercialize a new generation of glucose monitoring products in Japan.

Read more...

Freya Pharma Solutions, a pharmaceutical company dedicated to developing effective pharmaceutical therapies for women diagnosed with Female Sexual Disorders announced today

Read more...

Arcellx, Inc. a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced

Read more...

RK Pharma Inc, a vertically integrated pharmaceutical company today announced the successful completion of the acquisition of VGYAAN Pharmaceuticals LLC. The acquisition of VGYAAN Pharmaceuticals aligns strongly with our growth strategy

Read more...

Oliva Therapeutics, LLC, a healthcare company focused on product commercialization, sales, marketing, distribution, and promotion, announced today a long-term partnership with Rio Biopharmaceuticals, Inc., a subsidiary of the EMS S/A Pharma

Read more...

Astellas Pharma Inc. and Cullgen Inc. today announced a research collaboration and exclusive option agreement to discover multiple innovative protein degraders.

Read more...

Eyebiotech Limited a clinical-stage ophthalmology biotechnology company, today announced the dosing of the first participants in its Phase 1b/2 AMARONE clinical trial in patients with diabetic

Read more...

Future Fields, a pioneering biotechnology company that has built the world’s first synthetic biology system to use fruit flies for recombinant protein production, and Jenthera Therapeutics, a gene editing company focused on delivery of the CRISPR ribonucleoproteins

Read more...

ACROBiosystems, through ACRO Certify and under its Aneuro brand, recently announced the launch of in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips. Together, two companies are committed to a collaborative

Read more...

Veristat, a scientific-minded global clinical research organization, has acquired Scinopsis, a European medical writing consultancy with a 17-year track record of delivering regulatory

Read more...

Lantern Pharma Inc. an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning platform with multiple

Read more...

Cyclo Therapeutics, Inc. a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,

Read more...

DTx Pharma, a biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotide platform, today announced

Read more...

MAK-System, a worldwide leader in Blood Management systems, is proud to announce an extended and strategic partnership with New York Blood Center Enterprises

Read more...

Sol-Gel Technologies, Ltd. an Israel-based dermatology company and Searchlight Pharma Inc. a private Canadian specialty pharmaceutical company, today announced the signing of exclusive

Read more...

Propanc Biopharma, Inc. a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced the Company’s strategic

Read more...

Ellipses Pharma a global drug development company focused on accelerating the development of new oncology treatments, today announces its intention to expedite further global clinical

Read more...

Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for regenerating bone and managing infection in bone and soft

Read more...

Agilent Technologies Inc.today announced new mass spectrometry solutions on show at the 71st ASMS Conference on Mass Spectrometry and Allied Topics, being held June 4 - 8 in Houston

Read more...

Eikon Therapeutics, Inc., a biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and science, today announced it has acquired

Read more...

Crowell & Moring International is joining forces with Roche, TogetHER for Health, CAPED and Jhpiego to raise awareness about the surge of breast and cervical cancer cases in the Asia-Pacific

Read more...

InDex Pharmaceuticals Holding AB today announced that a license agreement has been signed with Viatris Pharmaceutical Japan Inc.to register and commercialize cobitolimod in Japan

Read more...

Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved ABRYSVO™ the company’s bivalent RSV prefusion F vaccine, for the prevention

Read more...

MEI Pharma, Inc. today confirmed receipt of an unsolicited and non-binding proposal on May 23, 2023 from a group represented by Anson Advisors Inc. and Cable Car Capital LLC, as referenced

Read more...

Aragen Life Sciences , a leading Contract Research and Development Organization, and FAR Biotech, a US-based, AI-driven, computational drug discovery company, have announced

Read more...

Algiax Pharmaceuticals, today provided an update on its ongoing Phase 2a study with lead candidate AP-325 in patients with chronic neuropathic pain. As part of a planned mid-enrollment

Read more...

ME Pharma N.V. a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment , announces the American Society of Clinical

Read more...

Abiogen Pharma S.p.A., Italian leading company in the field of osteoarticular and bone metabolism diseases, is pleased to announce the acquisition of a 97,09% stake in EffRx Pharmaceuticals SA,

Read more...

Takeda Limited today announced that the U.S. Food and Drug Administration has granted priority review of the New Drug Application (NDA) for fruquintinib, a highly selective and potent inhibitor

Read more...

TME Pharma NV a biotechnology company specializing in the development of novel therapies for the treatment of cancer by targeting the tumor microenvironment, announces that the American

Read more...

AbCellera today announced a CA$701 million co-investment with the Governments of Canada and British Columbia to build new capabilities and infrastructure to develop innovative antibody-based

Read more...

Touchlight, a company pioneering enzymatic DNA production, a critical material in many new genetic medicine treatments, has completed the redevelopment and expansion of its UK

Read more...

Cumberland Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application

Read more...

Freenome, a privately held biotech company, announced today it has acquired Oncimmune Ltd, a UK-based global immunodiagnostics developer with a commercialized CE-IVD marked EarlyCDT

Read more...

Opentrons, a leader in lab automation, announces the launch of its Opentrons Flex robot, a new generation of affordable and easy-to-program liquid-handling lab robots designed to level the playing

Read more...

Asieris Pharmaceuticals , a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related

Read more...

ImaginAb, Inc., a global biotechnology company focused on the development of radiopharmaceuticals for the diagnosis and treatment of cancer, today announced lead selection

Read more...

Xscientia plc today announced that Sumitomo Pharma Co., Ltd. plans to initiate a Phase 1 clinical study of DSP-2342 in the United States. DSP-2342 is a highly-selective bispecific small molecule

Read more...

HiST Pharma through its wholly-owned Psoriasis Research Institute of Guangzhou announces today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug

Read more...

Juno Pharmaceuticals Canada a leader in the commercialization of specialty pharmaceuticals, announced the acquisition of Omega Laboratories one of Canada’s largest domestic specialty

Read more...

Melinta Therapeutics, LLC and Xediton Pharmaceuticals Inc (Xediton) today announced they have entered into an exclusive commercialization and licensing agreement for BAXDELA®

Read more...

Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved VEOZAHTM (fezolinetant) 45 mg once daily for the treatment of moderate to severe

Read more...

Kintor Pharmaceutical Limited a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the Phase II clinical trial of in-house

Read more...

Angelini Pharma, part of the privately owned Angelini Industries, and JCR Pharmaceuticals Co., Ltd. announced today that they entered into an exclusive global development

Read more...

Oncocross, a Seoul-based AI drug discovery and development biotech, announced the completion of phase 1 global clinical trial of OC514, a treatment targeting sarcopenia and other rare muscular

Read more...

Transgene a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the first patient has been dosed in Delivir, a Phase I clinical

Read more...

Zanrong Pharmaceutical Technology Co., Ltd. today announced an agreement with Roche to acquire the global rights to ZN-A-1041, an oral small molecule HER2 inhibitor. Zanrong

Read more...

Freya Pharma Solutions, a pharmaceutical company focusing on the development of effective pharmaceutical therapies for women diagnosed with Female Sexual Disorders (FSD), announced

Read more...

Bruker Corporation today announced that is has closed the acquisition of ZONTAL Inc. an innovative platform provider for the digital transformation of the analytical laboratory,

Read more...

Ascletis Pharma Inc. announces today that the China National Medical Products Administration has approved to conduct a Phase IIa clinical trial for ASC10 to treat respiratory syncytial virus

Read more...

Tetra Pharm Technologies develops and manufactures pharmaceutical drugs targeting the endocannabinoid system for the treatment of neuropathic pain, sclerosis and mental health disorders.

Read more...

OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that it has signed an option agreement with BGN

Read more...

XNK Therapeutics AB today announced that the company's autologous natural killer (NK) cell therapy candidate XNK04 will be evaluated in combination with an ADCC competent PD-L1 inhibitor

Read more...

Reprocell USA, a CRO, has been awarded a contract to provide support for Lantern Pharma's Phase 2 clinical trial entitled "A Study of LP-300 With Carboplatin and Pemetrexed in Never

Read more...

BioCentriq, Inc. and panCELLa, a Pluristyx Company, announced that they have signed a research agreement designed to evaluate the ability of panCELLa's genetically-engineered, induced Pluripotent Stem Cell (iPSC)-derived

Read more...

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the opening of its state-of-the-art radiopharmaceutical manufacturing facility. The 27,000 square foot good manufacturing practice (GMP) compliant facility

Read more...

Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first Premarket Approval (PMA) application for its companion diagnostic test, xT CDx. xT CDx is a 648-gene next-generation sequencing test for solid tumor profiling

Read more...

Guided Therapeutics, Inc. or the “Company”, the maker of LuViva, a rapid and painless cervical cancer detection system based on the Company’s patented biophotonic technology, provided an update regarding the start of its pivotal clinical trial. The results of this clinical study will be used to support the Company’s application for U.S. FDA approval

Read more...

Ubie Inc. has signed a comprehensive collaboration agreement with Takeda Pharmaceutical Co., Ltd. to promote digital transformation, which aims to guide people to appropriate medical care for rare diseases and gastrointestinal diseases. Since April 2021, Ubie and Takeda Pharmaceutical Co., Ltd. have been promoting digital transformation

Read more...

RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, today announced that the Company has received a clearance from the United States Food & Drug Administration (FDA) cleared its Investigational New Drug (IND) application a Phase I clinical trial for RV-1730

Read more...

TransCode Therapeutics, Inc., a leading clinical-stage oncology company committed to using its proprietary platform delivery system to defeat cancer, today announced a strategic expansion of its diverse product portfolio. New capabilities for TransCode’s TTX delivery platform are embodied

Read more...

Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion and recommended granting a marketing authorization for Cosentyx® (secukinumab) in adults with active moderate to severe hidradenitis suppurativa (HS).

Read more...

AMO Pharma Limited a privately held biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, today announced completion

Read more...

Global private investment firm, Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, establishes LumaCina business unit under Bridgewest

Read more...

Ascentage Pharma a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis Band age-related diseases, today announced that it recently

Read more...

TraceLink Inc., the leading digital network platform company connecting more than 290,000 entities across the Healthcare and Life Sciences industry, today announced Multienterprise Information

Read more...

Navamedic ASA a Nordic pharma company and provider of high-quality products to hospitals and pharmacies, has today amended its cash offer to acquire all shares in Sensidose AB

Read more...

Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office

Read more...

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced completion of the safety evaluation stage of the highest dose cohort of patients with acute myeloid leukemia (AML) who relapsed after or were refractory

Read more...

Zucara Therapeutics Inc., a diabetes-focused life sciences company developing the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigational New Drug ("IND") application for ZT-01 for the prevention

Read more...

Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that the United States Food and Drug Administration (FDA) has approved the company's high potency vial line to manufacture a commercial product.

Read more...

Nordic Capital has agreed to acquire a majority share in corpuls to support the Company's next phase of growth, in partnership with the founding family. corpuls is an innovative medical

Read more...

Everest Medicines a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that it has signed

Read more...

AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved expanding the indication of QULIPTA® (atogepant) for the preventive treatment of migraine in adults. The approval makes QULIPTA the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist approved to prevent episodic and chronic migraine.

Read more...

Eli Lilly and Company announced today that it will invest an additional $1.6 billion and add another 200 new jobs at its two new manufacturing sites within LEAP Innovation Park in Boone County, bringing the company's total commitment to $3.7 billion and up to 700 new jobs. The company also today committed $15 million over five years to the Ivy Tech

Read more...

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced that it has entered into an agreement with Fulgent Genetics a technology-based

Read more...

LyGenesis, Inc., a clinical-stage biotechnology company developing allogenic cell therapies for large unmet needs, and Imagine Pharma, a biotechnology company focused on the development

Read more...

MGC Pharmaceuticals Ltd, a European based pharmaceutical company specializing in the development and supply of affordable, ethically produced plant-inspired medicines, announces

Read more...

Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced the U.S. Food and Drug Administration granted Orphan Drug Designation

Read more...

Nuance Pharma announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease of its novel solution Ensifentrine in mainland China.

Read more...

Torrent Pharma has begun shipping the generic version of Xeris's Keveyis®, 50mg tablets, following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.

Read more...

SciSparc Ltd., a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted final approval from the Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, required to commence the Company’s Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome

Read more...

Dipharma Francis S.r.l., a global CDMO and leading manufacturer of New Chemical Entities (NCE), Generic Active Pharmaceutical Ingredients and advanced Intermediates, announced today the completion of the expansion of its Research and Development Center for small molecules at its Headquarters located in Baranzate, close to Milan

Read more...

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced interim data demonstrating the potential of CPI-818, the Company’s ITK inhibitor, for the treatment of T cell lymphoma (TCL) at the 10th Whistler Global Summit on Hematologic Malignancies, which took place March 29 to April 2, 2023 in Whistler British Columbia, Canada

Read more...

Genenta Science, a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the license agreement with Ospedale San Raffaele (OSR) has been amended and restated to provide access to all solid tumor indications

Read more...

REGiMMUNE Limited, a biotechnology company focused on developing innovative immunotherapies for immune disorders and cancer, and San Fu Biotech, a subsidiary of San Fu

Read more...

CMP Pharma announced today that in order to mitigate drug shortage concerns, the FDA's CDER Office of Compliance has granted a shelf life extension for CMP Development LLC Potassium

Read more...

Athos Therapeutics, Inc. a clinical-stage biotechnology company pioneering the development of artificial intelligence-based precision small molecule therapeutics for patients with autoimmune

Read more...

Medical technology company Scivita Medical Technology Co., Ltd. and Boston Scientific one of the leading medical technology companies worldwide, have officially signed a Strategic Agreement

Read more...

Astellas Pharma Inc. today announced that it has entered into an agreement with Roche Diabetes Care Japan Co., Ltd. for the development and commercialization of Roche Diabetes Care's

Read more...

Celularity Inc. a biotechnology company developing placental-derived allogenic cell therapies and biomaterial products announces that it has entered into an exclusive distribution agreement

Read more...

Aadi Bioscience, Inc. a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR

Read more...

Pherecydes Pharma a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announces that it has been selected for the 2023

Read more...

Mitsubishi Tanabe Pharma America, Inc. today announced it has completed enrollment for the global, multi-center, double-blind, Phase 3b study evaluating the long-term efficacy and safety

Read more...

FSD Pharma Inc. a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory

Read more...

TaiGen Biotechnology Company, Limited today announces that they have signed an exclusive licensing agreement with Joincare Pharmaceutical Group Industry Co., Ltd., a top 10 China

Read more...

Jacobio Pharma announced it has entered into a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate the combination of Jacobio's CD73 monoclonal antibody JAB-BX102

Read more...

The 2023 Annual Meeting of American Academy of Dermatology Association was held from 17 to 21 March 2023 in New Orleans, Louisiana, United States. As one of the largest, most influential

Read more...

Stevanato Group S.p.A. a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced

Read more...

Labstat Inc., A Certified Group Company, has entered into a partnership with Toxys to offer the ToxTracker assay at its Kitchener, Ontario laboratory. ToxTracker is a state-of-the-art stem

Read more...

DelSiTech Ltd, a Finnish drug delivery and drug development company, today announces that it has been awarded a grant from the Bill & Melinda Gates Foundation to develop

Read more...

Nippon Express a group company of NIPPON EXPRESS HOLDINGS, INC., became the first Japanese forwarder to join Pharma.Aero on January 25 this year.

Read more...

Optimism is on the rise as the American Cancer Society is reporting that the five-year survival rate for those diagnosed with pancreatic has increased to 12%—representing an increase of 1% over

Read more...

Astellas Pharma Inc. today announced positive topline results from the Phase 3 China ARCHES study of XTANDI® plus androgen deprivation therapy in men with metastatic hormone-sensitive

Read more...

On March 7th, 2023, Suzhou Porton Advanced Solutions Ltd. and Bennu Biotherapeutics announced a strategic partnership to advance cell and gene therapy R&D pipelines.

Read more...

Sumitovant Biopharma Ltd.and Myovant Sciences Ltd. announced today that Sumitovant has successfully completed its acquisition of Myovant originally announced October 23, 2022.

Read more...

Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the first generic version of Allergan's Pylera® 140 mg, 125 mg and 125

Read more...

Shuttle Pharmaceuticals Holdings, Inc.a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with

Read more...

Microbion Corporation today announced that a Phase 2, randomized, controlled study has been initiated to assess the safety and efficacy of topical pravibismane for the treatment of subjects

Read more...

InvoX Pharma Limited a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited with an advancing pipeline of innovative products, today announces that it has successfully

Read more...

IBSA Pharma announced today that it has entered into an agreement with Mark Cuban Cost Plus Drug Company, PBC to offer Tirosint® oral capsules at a low cash price via the Cost Plus Drugs

Read more...

On the eve of International Women’s Day, BioSyent Inc. celebrates the Canadian launch of FeraMAX® Pd Maintenance 45 by its subsidiary, BioSyent Pharma Inc. FeraMAX® Pd

Read more...

Sun Pharmaceutical Industries Limited today announced the successful completion of its acquisition of Concert Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical

Read more...

Harbour BioMed a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology,

Read more...

Finding easy-to-understand information about pediatric liver diseases that even kids can relate to has been a challenge, that's why the American Liver Foundation is launching a new pediatric liver

Read more...

Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is opening a new office in Cambridge Innovation Centre, CIC, marking a new era towards the company's rising ambition on serving and collaborating with world's best biotech start-ups and ventures.

Read more...

The pioneer of innovative proteomic and glycomic research solutions, today announced the acquisitions of Click Chemistry Tools, a manufacturer of click chemistry linkers and labeling

Read more...

The ERP Biomarker Qualification Consortium announced today the successful completion of a pharma industry-sponsored study to measure the electrophysiologic effects of ketamine on healthy brain function.

Read more...

ArisGlobal , the leading provider of life sciences software that automates the core functions of drug development with its end-to-end LifeSphere® LifeSphere® technology platform, today announced

Read more...

NATCO Pharma Limited announces launch of Pomalidomide Capsules in Canada, the first generic alternative to POMALYST® brand in the country approved by Health Canada. Pomalidomide is used in combination with Dexamethasone and Bortezomib for the treatment of adult patients

Read more...

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a multi-year, strategic collaboration with Pfizer in which the two companies are working together to further AI and machine learning-driven efforts in therapeutic development. The goal of this collaboration

Read more...

AMO Pharma Limited, a privately held biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, today announced that the UK

Read more...

Mitsubishi Tanabe Pharma America, Inc. today announced the publication of results from the global, multi-center, open-label, Phase 3 clinical trial evaluating the long-term safety

Read more...

TransCode Therapeutics, Inc., the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the signing of a non-binding letter of intent and a joint research and development agreement (JDA) with industrial biotechnology and genome editing expert, BRAIN Biotech AG

Read more...

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. (“Ono”), for CUE-401, a bispecific protein

Read more...

Pharmatech Associates today announced a strategic alliance that brings PCM expertise and capabilities to the marketplace to tackle drug shortages and supply chain issues by providing drug sponsors and manufacturers a more effective means of making finished drug products

Read more...

MMS Holdings, a data-focused contract research organization (CRO) – announced its partnership with the Institute for Advanced Clinical Trials (I-ACT) to accelerate the development of life-saving therapeutics, including vaccines, medicines, and medical devices for children.

Read more...

Biocytogen Pharmaceuticals Co., Ltd. today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets. The Project combines

Read more...

Theragent, a cell therapy CDMO focused on advancing next-generation cancer and rare disease treatments, has signed a multi-year exclusive contract with Insight68, an AI-driven software provider

Read more...

NS Pharma, Inc. announced today the first patient enrollment in a Phase 2 clinical study of NS-018 an investigational treatment for myelofibrosis a rare and incurable blood cancer.

Read more...

National Resilience, Inc., a technology-focused manufacturing company dedicated to broadening access to complex medicines, today announced a 10-year biomanufacturing partnership with a leading pharmaceutical company for its portfolio of services across Process and Analytical Development, Drug Substance, and Drug Product manufacturing

Read more...

Renexxion Ireland Limited, a private biopharmaceutical company committed to providing innovative medicines to patients with high unmet need for gastrointestinal disorders, will is pleased to

Read more...

Taiwan-based Formosa Pharmaceuticals announced today that the company has entered into a collaboration agreement with Eyenovia, Inc. for the development of novel ophthalmic therapeutics.

Read more...

GreenLab, Inc. announces launch of the biotech startup's proprietary vector technology platform. GreenLab Vector Technology greens recombinant protein manufacturing by transforming novel

Read more...

As federal authorities widen a multistate investigation into antibiotic-resistant Pseudomonas aeruginosa bacterial contamination linked to EzriCare Artificial Tears eye drops, a woman has now filed a federal lawsuit against EzriCare and retailer Walmart after using the eye drops and suffering

Read more...

ESSA Pharma Inc. a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that further analyses of initial clinical data

Read more...

PharmaNutra S.p.A. a company specialised in mineral and iron-based nutritional supplements and medical devices for muscles and joints, is ready to face the great challenge of the FIA World

Read more...

Roche today announced that it has expanded its collaboration with Janssen Biotech Inc. to create companion diagnostics for targeted therapies, further strengthening research and innovation activities.

Read more...

Astellas Pharma Inc. today announced its commitment to achieve net zero greenhouse gas emissions by 2050.Astellas Pharma Inc. today announced its commitment to achieve net zero greenhouse gas emissions by 2050.

Read more...

Envision Pharma Group a leading global technology-enabled commercialization, integrated medical capabilities and solutions, and data analytics partner to the life sciences industry, announced

Read more...

Kenya Medical Research Institute NEC Corporation and Nagasaki University have developed an immunization management system based on digital biometrics for newborns in Kenya. Validation

Read more...

Ellipses Pharma, a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for EP0042

Read more...

Seqens Group, an integrated leader in the development and manufacture of active pharmaceutical ingredients (APIs) and intermediates, today announced that it has opened Seqens Boston R&D Center, a state-of-the-art, 15,000 square-foot R&D center in Devens, Mass. Serving as one of the company’s global centers

Read more...

Ajinomoto Co., Inc.today announced a license agreement with Exelixis, Inc. to develop AJICAP , its proprietary site-specific bioconjugation and Linker Technology of Ajinomoto Co., in the development of certain Exelixis Antibody-Drug Conjugate programs.Exelixis is a commercially successful Exelixis is a commercially successful

Read more...

Hemab Therapeutics, a clinical-stage biotechnology company developing next-generation therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the first patient has been dosed in a Phase 1/2 study evaluating HMB-001 for the treatment of the severe bleeding disorder Glanzmann

Read more...